Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage

Arthritis Research and Therapy

Volumn 15, Issue SUPPL 3, 2013, Pages

  Sostres, Carlos ^a,b   Gargallo, Carla J ^a,b   Lanas, Angel ^a,b,c,d  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AZAPROPAZONE; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIFLUNISAL; ETORICOXIB; HYDROGEN SULFIDE; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LOXOPROFEN; MELOXICAM; NAPROXCINOD; NAPROXEN; NIMESULIDE; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; SULINDAC; TENOXICAM; UNINDEXED DRUG; VALDECOXIB; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANEMIA; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTEROPATHY; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GUT PERMEABILITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOSPITALIZATION; HUMAN; INTESTINE; LOW DRUG DOSE; MALABSORPTION; META ANALYSIS; MORTALITY; MUCOSAL ULCERATION; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; TREND STUDY; UPPER GASTROINTESTINAL TRACT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; INTESTINE MUCOSA; PATHOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL MUCOSA; PYRAZOLES; RISK FACTORS; SULFONAMIDES;

EID: 84880754530     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4175     Document Type: Review

References (64)

1. Brune K, Hinz B. The discovery and development of antiinflammatory drugs. Arthritis Rheum 2004, 50:2391-2399.
2. Singh G. Gastrointestinal complications of prescription and over-thecounter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther 2000, 7:115-121.
3. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosaand dyspeptic symptoms in arthritic patients during chronic steroidal antiinflammatory drug use. Am J Gastroenterol 1987, 82:1153-1158.
4. Lanas A, Hunt R. Prevention of anti-inflammatory drug induced gastrointestinal damage: beneficts and risks of therapeutic strategies. Ann Med 2006, 38:415-428.
5. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005, 7:R644-R665.
6. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987, 28:527-532.
7. Perez Gutthann S, Garcia Rodriguez LA, Raiford DS. Individual nonsteroidal anti-inflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997, 8:18-24.
8. Hernandez-Diaz S, Garcia-Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/ perforation. An overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000, 160:2093-2099.
9. Huang J-Q, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet 2002, 359:14-22.
10. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010, 24:121-132.
11. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002, 359:14-22.
12. Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK, Lee YT, Chan CS, Li EK, Woo J. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997, 350:975-979.
13. Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T, Hui Y, Chan HL, Chan CS, Hui E, Woo J, Sung JJ. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002, 359:9-13.
14. Castellsague J, Riera-Guardia N, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A, Nicotra F, Sturkenboom M, Perez-Gutthann S, Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012, 35:1127-1146. Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project.
15. Rostom A, Muir K, Dubé C, Jolicoeur E, Boucher M, Joyce J, Tugwell P, Wells GW. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007, 5:818-828.
16. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000, 284:1247-1255.
17. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ, TARGET Study Group Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004, 364:665-674. TARGET Study Group.
18. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G, SUCCESS-I Investigators Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med 2006, 119:255-266. SUCCESS-I Investigators.
19. Rostom A, Muir K, Dube C, Lanas A, Jolicoeur E, Tugwell P. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of unsaid with gastroprotection and COX-2 inhibitors. Drug Health Patient Safety 2009, 1:1-25.
20. Jarupongprapa S, Ussavasodhi P, Katchamart W. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol 2012,
21. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011, 342:c7086.
22. Fiorucci S, Distrutti E. COXIBs, CINODs and H2S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs. Curr Med Chem 2011, 18:3494-3505.
23. Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004, 50:2433-2440.
24. Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009, 29:938-946.
25. Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology 2007, 132:2320-2327.
26. Lanas A, García-Rodríguez LA, Polo-Tomás M, Ponce M, Quintero E, Perez-Aisa MA, Gisbert JP, Bujanda L, Castro M, Muñoz M, Del-Pino MD, Garcia S, Calvet X. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment Pharmacol Ther 2011, 33:585-591.
27. Lanas A, García-Rodríguez LA, Polo-Tomás M, Ponce M, Alonso-Abreu I, Perez-Aisa MA, Perez-Gisbert J, Bujanda L, Castro M, Muñoz M, Rodrigo L, Calvet X, Del-Pino D, Garcia S. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009, 104:1633-1641.
28. Lanas A, Sopeña F. Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications. Gastroenterol Clin North Am 2009, 38:333-352.
29. Lanas A, Perez-Aisa MA, Feu F, Ponce J, Saperas E, Santolaria S, Rodrigo L, Balanzo J, Bajador E, Almela P, Navarro JM, Carballo F, Castro M, Quintero E, Investigators of the Asociación Española de Gastroenterología (AEG) A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005, 100:1685-1693. Investigators of the Asociación Española de Gastroenterología (AEG).
30. Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, Cannon CP. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal antiinflammatory drug diclofenac. Gastroenterology 2008, 135:1517-1525.
31. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005, 3:55-59.
32. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005, 128:1172-1178.
33. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG, Investigators Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005, 3:133-141. Investigators.
34. Moore RA, Derry S, McQuay HJ. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromiumlabelled erythrocytes. Arthritis Res Ther 2008, 10:R7.
35. Smecuol E, Pinto Sanchez MI, Suarez A, Argonz JE, Sugai E, Vazquez H, Litwin N, Piazuelo E, Meddings JB, Bai JC, Lanas A. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol 2009, 7:524-529.
36. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005, 3:133-141.
37. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Aisenberg J, Bhadra P, Berger MF. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 2007, 25:1211-1222.
38. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010, 376:173-179. A published erratum appears in Lancet 2011, 378:228.
39. Hedenbro JL, Wetterberg P, Vallgren S, Bergqvist L. Lack of correlation between fecal blood loss and drug-induced gastric mucosal lesions. Gastrointest Endosc 1998, 34:247-251.
40. Morris AJ, Madhok R, Sturrock RD, Capell HA, MacKenzie JF. Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal antiinflammatory drugs. Lancet 1991, 337:520.
41. Lanas A, Panés J, Piqué JM. Clinical implications of COX-1 and/or COX-2 inhibition or the distal gastrointestinal tract. Curr Pharm Des 2003, 9:2253-2266.
42. Fortun PJ, Hawkey CJ. Nonsteroidal anti-inflammatory drugs and the small intestine. Curr Opin Gastroenterol 2005, 21:169-175.
43. Bjarnason I, Williams P, Smethurst P, Peters TJ, Levi AJ. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 1986, 27:1292-1297.
44. Bjarnason I, Smethurst P, Macpherson A, Walker F, McElnay JC, Passmore AP, Menzies IS. Glucose and citrate reduce the permeability changes caused by indomethacin in humans. Gastroenterology 1992, 102:1546-1550.
45. Smecuol E, Bai JC, Sugai E, Vazquez H, Niveloni S, Pedreira S, Mauriño E, Meddings J. Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs. Gut 2001, 49:650-655.
46. Sigthorsson G, Crane R, Simon T, Hoover M, Quan H, Bolognese J, Bjarnason I. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut 2000, 47:527-532.
47. Bjarnason I, Zanelli G, Smith T, Prouse P, Williams P, Smethurst P, Delacey G, Gumpel MJ, Levi AJ. Nonsteroidal anti-inflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987, 93:480-489.
48. Bjarnason I, Zanelli G, Prouse P, Smethurst P, Smith T, Levi S, Gumpel MJ, Levi AJ. Blood and protein loss via small intestinal inflammation induced by nonsteroidal antiinflammatory drugs. Lancet 1987, 2:711-714.
49. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992, 327:749-754.
50. Costamagna G, Shah SK, Riccioni ME, Foschia F, Mutignani M, Perri V, Vecchioli A, Brizi MG, Picciocchi A, Marano P. A prospective trial comparing small bowel radiographs and video capsule endoscopy for suspected small bowel disease. Gastroenterology 2002, 123:999-1005.
51. Kurahara K, Matsumoto T, Iida M, Honda K, Yao T, Fujishima M. Clinical and endoscopic features of nonsteroidal anti-inflammatory drug-induced colonic ulcerations. Am J Gastroenterol 2001, 96:473-480.
52. Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and non-ulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992, 103:862-869.
53. Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sáinz R. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997, 112:683-689.
54. Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003, 124:288-292.
55. Lanas A. Update on gastrointestinal disorders associated with nonsteroidal anti-inflammatory drugs. Gastroenterol Hepatol 2008, 31(SuppL 4):35-41.
56. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002, 26:2104-2110.
57. Laine L, Smith R, Min K, Chen C, Dubois RW. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2006, 24:751-767.
58. Wilcox CM, Alexander LN, Cotsonis GA, Clark WS. Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding. Dig Dis Sci 1997, 42:990-997.
59. Tramèr MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000, 85:169-182.
60. Lim CH, Vani D, Shah SG, Everett SM, Rembacken BJ. The outcome of suspected upper gastrointestinal bleeding with 24-hour access to upper gastrointestinal endoscopy: a prospective cohort study. Endoscopy 2006, 38:581-585.
61. Sadic J, Borgström A, Manjer J, Toth E, Lindell G. Bleeding peptic ulcer - time trends in incidence, treatment and mortality in Sweden. Aliment Pharmacol Ther 2009, 30:392-398.
62. Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology 2007, 132:2320-2327.
63. Brown TJ, Hooper L, Elliott RA, Payne K, Webb R, Roberts C, Rostom A, Symmons D. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess 2006, 10:iii-iv. xi-xiii, 1-183.
64. Lanas A. Editorial: upper GI bleeding-associated mortality: challenges to improving a resistant outcome. Am J Gastroenterol 2010, 105:90-92.